BR0015523A - Métodos para o tratamento e para a prevenção de condições neurodegenerativas - Google Patents

Métodos para o tratamento e para a prevenção de condições neurodegenerativas

Info

Publication number
BR0015523A
BR0015523A BR0015523-3A BR0015523A BR0015523A BR 0015523 A BR0015523 A BR 0015523A BR 0015523 A BR0015523 A BR 0015523A BR 0015523 A BR0015523 A BR 0015523A
Authority
BR
Brazil
Prior art keywords
treatment
methods
prevention
neurodegenerative conditions
adatanserin
Prior art date
Application number
BR0015523-3A
Other languages
English (en)
Inventor
Magid Abdel-Megid Abou-Gharbia
James Edward Barrett
Wayne Everett Childers Jr
John Allen Moyer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0015523A publication Critical patent/BR0015523A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Meat And Fish (AREA)

Abstract

"MéTODOS PARA O TRATAMENTO E PARA A PREVENçãO DE CONDIçõES NEURODEGENERATIVAS". A adatanserina é útil para o tratamento de distúrbios neurodegenerativos, de dor crónica e de outros distúrbios associados com a liberação disfuncional de glutamato. Os métodos de tratamento dos mesmos compreendem a administração de uma quantidade terapeuticamente eficaz de adatanserina ou de um sal farmacêutico da mesma, a um paciente que necessita do dito tratamento.
BR0015523-3A 1999-11-12 2000-11-10 Métodos para o tratamento e para a prevenção de condições neurodegenerativas BR0015523A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43921999A 1999-11-12 1999-11-12
PCT/US2000/030973 WO2001034136A2 (en) 1999-11-12 2000-11-10 Use of adatanserin for the treatment of neurodegenerative conditions

Publications (1)

Publication Number Publication Date
BR0015523A true BR0015523A (pt) 2002-10-22

Family

ID=23743796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015523-3A BR0015523A (pt) 1999-11-12 2000-11-10 Métodos para o tratamento e para a prevenção de condições neurodegenerativas

Country Status (22)

Country Link
EP (2) EP1242089B1 (pt)
JP (1) JP2003513915A (pt)
KR (1) KR100757226B1 (pt)
CN (1) CN100469368C (pt)
AT (1) ATE291919T1 (pt)
AU (1) AU773733B2 (pt)
BR (1) BR0015523A (pt)
CA (1) CA2390797A1 (pt)
CZ (1) CZ298535B6 (pt)
DE (1) DE60019166T2 (pt)
EA (1) EA006099B1 (pt)
ES (1) ES2235998T3 (pt)
HK (1) HK1046505B (pt)
HU (1) HUP0301847A3 (pt)
IL (1) IL149264A0 (pt)
MX (1) MXPA02004654A (pt)
NO (1) NO322371B1 (pt)
NZ (1) NZ518814A (pt)
PL (1) PL355014A1 (pt)
PT (1) PT1242089E (pt)
WO (1) WO2001034136A2 (pt)
ZA (1) ZA200204682B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1242089B1 (en) * 1999-11-12 2005-03-30 Wyeth Use of adatanserin for the treatment of acute neurodegenerative disorders
EP2236511A4 (en) 2007-12-21 2011-04-13 Alla Chem Llc LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
EP1242089B1 (en) * 1999-11-12 2005-03-30 Wyeth Use of adatanserin for the treatment of acute neurodegenerative disorders

Also Published As

Publication number Publication date
DE60019166D1 (de) 2005-05-04
ZA200204682B (en) 2003-09-11
PT1242089E (pt) 2005-08-31
NO322371B1 (no) 2006-09-25
AU1656701A (en) 2001-06-06
AU773733B2 (en) 2004-06-03
EP1242089B1 (en) 2005-03-30
CZ20021629A3 (cs) 2003-06-18
IL149264A0 (en) 2002-11-10
HK1046505A1 (en) 2003-01-17
ATE291919T1 (de) 2005-04-15
EP1547597A3 (en) 2006-09-27
JP2003513915A (ja) 2003-04-15
CN1390128A (zh) 2003-01-08
HK1046505B (zh) 2005-06-03
EA006099B1 (ru) 2005-08-25
ES2235998T3 (es) 2005-07-16
EP1242089A2 (en) 2002-09-25
MXPA02004654A (es) 2004-09-10
NO20022187D0 (no) 2002-05-07
EA200200559A1 (ru) 2002-12-26
CA2390797A1 (en) 2001-05-17
KR100757226B1 (ko) 2007-09-11
WO2001034136A2 (en) 2001-05-17
WO2001034136A3 (en) 2002-03-21
CN100469368C (zh) 2009-03-18
NO20022187L (no) 2002-05-07
PL355014A1 (en) 2004-03-22
NZ518814A (en) 2005-08-26
KR20020073132A (ko) 2002-09-19
HUP0301847A2 (hu) 2003-09-29
DE60019166T2 (de) 2006-05-11
HUP0301847A3 (en) 2004-01-28
CZ298535B6 (cs) 2007-10-31
EP1547597A2 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
BR0115166A (pt) Combinações de drogas (por exemplo, cloropromazina e pentamidina) para o tratamento de distúrbios neoplásticos
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
BR0010669A (pt) Método para o tratamento de fibrose usando um antagonista da subunidade alfa-4 da integrina
FR2712811B1 (fr) Procédé pour lutter contre l'adiposite et compositions utilisables à cet effet.
YU61598A (sh) Tretmani bolesti uz korišćenje citokina
BR0306777A (pt) Tratamento de dor, inflamação e distúrbios relacionados à inflamação, com uma combinação de um inibidor seletivo de ciclooxigenase-2 e aspirina
BR0015523A (pt) Métodos para o tratamento e para a prevenção de condições neurodegenerativas
BR0012942A (pt) Aplicação de flupirtin para a diminuição de dores em doenças articulares degenerativas de cães e gatos
BR0017367A (pt) Uso de melagatran ou de um seu derivado farmaceuticamente aceitável, método de tratamento de um distúrbio isquêmico em um paciente tendo, ou sob risco de ter, fibrilação atrial não-valvular, e, formulação farmacêutica
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
BR9709223A (pt) Estimulação dos mecanismos de defesa do hospedeiro contra tumores.
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
BR9914570A (pt) Processo para o tratamento da esquizofrenia bem como agentes para o emprego neste processo
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/506, A61P 25/28

Ipc: A61K 31/00 (2009.01)

B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, REQUERIDA ATRAVES DA PETICAO NO 20090068304/RJ DE 14.07.2009.